{"pmid":32425152,"title":"Medicines for the Treatment Of COVID-19: Awaiting the Evidence.","text":["Medicines for the Treatment Of COVID-19: Awaiting the Evidence.","The novel severe acute respiratory syndrome coronavirus 2 is the cause of Coronavirus Disease 2019, a new illness with no effective treatment or vaccine that has reached pandemic proportions. In this document, we analyze how health authorities and agencies around the world position themselves regarding the off-label use of repurposed drugs or new investigational drugs to treat Coronavirus Disease 2019. We review the most promising candidate medicines, including available evidence, clinical recommendations and current options for access. Our concluding remarks stress the importance of administering off-label and investigational drugs in the setting of clinical trials, or at least in standardized scenarios, to generate as much scientific knowledge as achievable while engaging in the best efforts to treat patients and save lives.","Acta Med Port","Marto, Natalia","Monteiro, Emilia C","32425152"],"abstract":["The novel severe acute respiratory syndrome coronavirus 2 is the cause of Coronavirus Disease 2019, a new illness with no effective treatment or vaccine that has reached pandemic proportions. In this document, we analyze how health authorities and agencies around the world position themselves regarding the off-label use of repurposed drugs or new investigational drugs to treat Coronavirus Disease 2019. We review the most promising candidate medicines, including available evidence, clinical recommendations and current options for access. Our concluding remarks stress the importance of administering off-label and investigational drugs in the setting of clinical trials, or at least in standardized scenarios, to generate as much scientific knowledge as achievable while engaging in the best efforts to treat patients and save lives."],"journal":"Acta Med Port","authors":["Marto, Natalia","Monteiro, Emilia C"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425152","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.20344/amp.13908","keywords":["covid-19/drug therapy","coronavirus","coronavirus infections/drug therapy"],"topics":["Treatment"],"weight":1,"_version_":1667352728778571776,"score":9.490897,"similar":[{"pmid":32305589,"pmcid":"PMC7162749","title":"Combating Devastating COVID -19 by Drug Repurposing.","text":["Combating Devastating COVID -19 by Drug Repurposing.","Despite advances in Drug Discovery, the viral infections always remain the major challenge for the Scientists across the globe. The recent pandemic COVID-19 viral infection has created a disastrous situation all over the world. As no drug is available to treat such life- threatening disease and the mortality rate is significantly increased due to COVID-19; there is an utmost need to cure the infection by Drug Repurposing. Some counties are against the use of these drugs because of adverse effects associated with drug repurposing and lack of statistically significant clinical data but they were found to be effective in some countries to treat affected COVID-19 patients (Off label/ Investigational). The article emphases the possible drug candidates in the treatment of COVID-19 infection. Most of these drugs were found to be effective in in vitro studies. There is a need to reassess the in vitro data and to carry out randomised clinical trials. Further investigations of these drugs are recommended on the priority basis.","Int J Antimicrob Agents","Pawar, Ashish Yashwantrao","32305589"],"abstract":["Despite advances in Drug Discovery, the viral infections always remain the major challenge for the Scientists across the globe. The recent pandemic COVID-19 viral infection has created a disastrous situation all over the world. As no drug is available to treat such life- threatening disease and the mortality rate is significantly increased due to COVID-19; there is an utmost need to cure the infection by Drug Repurposing. Some counties are against the use of these drugs because of adverse effects associated with drug repurposing and lack of statistically significant clinical data but they were found to be effective in some countries to treat affected COVID-19 patients (Off label/ Investigational). The article emphases the possible drug candidates in the treatment of COVID-19 infection. Most of these drugs were found to be effective in in vitro studies. There is a need to reassess the in vitro data and to carry out randomised clinical trials. Further investigations of these drugs are recommended on the priority basis."],"journal":"Int J Antimicrob Agents","authors":["Pawar, Ashish Yashwantrao"],"date":"2020-04-20T11:00:00Z","year":2020,"_id":"32305589","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.ijantimicag.2020.105984","keywords":["covid-19","corona virus","drug repurposing","sars-cov-2"],"locations":["Scientists"],"topics":["Treatment"],"weight":1,"_version_":1666138493396451328,"score":144.19635},{"pmid":32374264,"title":"Delivering Benefits at Speed through Real-World Repurposing of Off-Patent Drugs: The COVID-19 Pandemic as a Case in Point.","text":["Delivering Benefits at Speed through Real-World Repurposing of Off-Patent Drugs: The COVID-19 Pandemic as a Case in Point.","UNSTRUCTURED: Real-world drug repurposing - the immediate 'off-label' prescribing of drugs to address urgent clinical need - is a widely overlooked opportunity. Off-label prescribing (i.e. for a non-approved indication) is legal in most countries, and tends to shift the burden of liability or cost to physicians and patients, respectively. Nevertheless, health crises may mean that real-world repurposing is the only realistic source of solutions. Optimal real-world repurposing requires a track record of safety, affordability, and access for drug candidates. Although thousands of such drugs are already available, there is no central repository of off-label uses to facilitate immediate identification and selection of potentially useful interventions during public health crises. Using the current COVID-19 pandemic as an example, we provide a glimpse of the extensive literature that supports the rationale behind six generic drugs, in four classes, all of which are affordable, supported by decades of safety data, and target the underlying pathophysiology that makes COVID-19 so deadly. This paper briefly summarizes why cimetidine or famotidine, dipyridamole, fenofibrate or bezafibrate, and sildenafil citrate, are worth considering for patients with COVID-19. Clinical trials to assess efficacy are already underway for famotidine, dipyridamole, and sildenafil, and further trials of all these agents will be important in due course. These examples also reveal the unlimited opportunity to future-proof our healthcare systems by proactively mining, synthesizing, cataloging, and evaluating the off-label treatment opportunities of thousands of safe, well established, and affordable generic drugs.","JMIR Public Health Surveill","Rogosnitzky, Moshe","Berkowitz, Esther","Jadad, Alejandro R","32374264"],"abstract":["UNSTRUCTURED: Real-world drug repurposing - the immediate 'off-label' prescribing of drugs to address urgent clinical need - is a widely overlooked opportunity. Off-label prescribing (i.e. for a non-approved indication) is legal in most countries, and tends to shift the burden of liability or cost to physicians and patients, respectively. Nevertheless, health crises may mean that real-world repurposing is the only realistic source of solutions. Optimal real-world repurposing requires a track record of safety, affordability, and access for drug candidates. Although thousands of such drugs are already available, there is no central repository of off-label uses to facilitate immediate identification and selection of potentially useful interventions during public health crises. Using the current COVID-19 pandemic as an example, we provide a glimpse of the extensive literature that supports the rationale behind six generic drugs, in four classes, all of which are affordable, supported by decades of safety data, and target the underlying pathophysiology that makes COVID-19 so deadly. This paper briefly summarizes why cimetidine or famotidine, dipyridamole, fenofibrate or bezafibrate, and sildenafil citrate, are worth considering for patients with COVID-19. Clinical trials to assess efficacy are already underway for famotidine, dipyridamole, and sildenafil, and further trials of all these agents will be important in due course. These examples also reveal the unlimited opportunity to future-proof our healthcare systems by proactively mining, synthesizing, cataloging, and evaluating the off-label treatment opportunities of thousands of safe, well established, and affordable generic drugs."],"journal":"JMIR Public Health Surveill","authors":["Rogosnitzky, Moshe","Berkowitz, Esther","Jadad, Alejandro R"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32374264","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.2196/19199","locations":["Optimal"],"e_drugs":["Cimetidine","Sildenafil Citrate","Fenofibrate","Dipyridamole","Famotidine","Bezafibrate"],"topics":["Treatment"],"weight":1,"_version_":1666138496484507648,"score":135.75505},{"pmid":32370766,"title":"Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines.","text":["Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines.","The coronavirus disease (COVID-19) pandemic has led to a global struggle to cope with the sheer numbers of infected persons, many of whom require intensive care support or eventually succumb to the illness. The outbreak is managed by a combination of disease containment via public health measures and supportive care for those who are affected. To date, there is no specific anti-COVID-19 treatment. However, the urgency to identify treatments that could turn the tide has led to the emergence of several investigational drugs as potential candidates to improve outcome, especially in the severe to critically ill. While many of these adjunctive drugs are being investigated in clinical trials, professional bodies have attempted to clarify the setting where the use of these drugs may be considered as off-label or compassionate use. This review summarizes the clinical evidence of investigational adjunctive treatments used in COVID-19 patients as well as the recommendations of their use from guidelines issued by international and national organizations in healthcare.","Mil Med Res","Xu, Xinni","Ong, Yew Kwang","Wang, De Yun","32370766"],"abstract":["The coronavirus disease (COVID-19) pandemic has led to a global struggle to cope with the sheer numbers of infected persons, many of whom require intensive care support or eventually succumb to the illness. The outbreak is managed by a combination of disease containment via public health measures and supportive care for those who are affected. To date, there is no specific anti-COVID-19 treatment. However, the urgency to identify treatments that could turn the tide has led to the emergence of several investigational drugs as potential candidates to improve outcome, especially in the severe to critically ill. While many of these adjunctive drugs are being investigated in clinical trials, professional bodies have attempted to clarify the setting where the use of these drugs may be considered as off-label or compassionate use. This review summarizes the clinical evidence of investigational adjunctive treatments used in COVID-19 patients as well as the recommendations of their use from guidelines issued by international and national organizations in healthcare."],"journal":"Mil Med Res","authors":["Xu, Xinni","Ong, Yew Kwang","Wang, De Yun"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32370766","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1186/s40779-020-00251-x","keywords":["adjunctive treatment","covid-19","chloroquine","convalescent plasma","corticosteroids","lopinavir-ritonavir","remdesivir","umifenovir"],"topics":["Treatment"],"weight":1,"_version_":1666138496380698625,"score":135.60098},{"pmid":32329520,"title":"Current pharmacological treatments for COVID-19: what's next?","text":["Current pharmacological treatments for COVID-19: what's next?","Starting from December 2019 the novel SARS-Cov-2 has spread all over the world, being recognized as the causing agent of COVID-19. Since nowadays no specific drug therapies neither vaccines are available for the treatment of COVID-19, drug repositioning may offer a strategy to efficiently control the clinical course of the disease and the spread of the outbreak. In this paper we aim to describe the main pharmacological properties, including data on mechanism of action, safety concerns and drug-drug interactions, of drugs currently administered in patients with COVID-19, focusing on antivirals and drugs with immune-modulatory and/or anti-inflammatory properties. Where available, data from clinical trials involving patients with COVID-19 were reported. Several studies have been registered worldwide and a number of drugs were repurposed to face the new health emergency of COVID-19. For many of these drugs, including lopinavir/ritonavir, remdesivir, favipiravir and tocilizumab, preliminary clinical trials seem to support their benefit in improving patients' clinical conditions. However, adequate clinical trials are necessary to reach any firm conclusion on the efficacy and safety profiles of these compounds. Even though drug repurposing is necessary, it requires caution. Too many drugs that are currently tested in patients with COVID-19 have peculiar safety profiles. In conclusion, while waiting for the development of effective preventive measures, such as vaccines, many clinical trials on drugs belonging to different therapeutic classes are currently underway. It is conceivable that very soon their results will help us in defining the best way to treat COVID-19 and reducing its symptoms and complications.","Br J Pharmacol","Scavone, Cristina","Brusco, Simona","Bertini, Michele","Sportiello, Liberata","Rafaniello, Concetta","Zoccoli, Alice","Berrino, Liberato","Racagni, Giorgio","Rossi, Francesco","Capuano, Annalisa","32329520"],"abstract":["Starting from December 2019 the novel SARS-Cov-2 has spread all over the world, being recognized as the causing agent of COVID-19. Since nowadays no specific drug therapies neither vaccines are available for the treatment of COVID-19, drug repositioning may offer a strategy to efficiently control the clinical course of the disease and the spread of the outbreak. In this paper we aim to describe the main pharmacological properties, including data on mechanism of action, safety concerns and drug-drug interactions, of drugs currently administered in patients with COVID-19, focusing on antivirals and drugs with immune-modulatory and/or anti-inflammatory properties. Where available, data from clinical trials involving patients with COVID-19 were reported. Several studies have been registered worldwide and a number of drugs were repurposed to face the new health emergency of COVID-19. For many of these drugs, including lopinavir/ritonavir, remdesivir, favipiravir and tocilizumab, preliminary clinical trials seem to support their benefit in improving patients' clinical conditions. However, adequate clinical trials are necessary to reach any firm conclusion on the efficacy and safety profiles of these compounds. Even though drug repurposing is necessary, it requires caution. Too many drugs that are currently tested in patients with COVID-19 have peculiar safety profiles. In conclusion, while waiting for the development of effective preventive measures, such as vaccines, many clinical trials on drugs belonging to different therapeutic classes are currently underway. It is conceivable that very soon their results will help us in defining the best way to treat COVID-19 and reducing its symptoms and complications."],"journal":"Br J Pharmacol","authors":["Scavone, Cristina","Brusco, Simona","Bertini, Michele","Sportiello, Liberata","Rafaniello, Concetta","Zoccoli, Alice","Berrino, Liberato","Racagni, Giorgio","Rossi, Francesco","Capuano, Annalisa"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32329520","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/bph.15072","keywords":["covid-19","anti-inflammatory agents","antivirals","clinical practice","clinical research","immuno-modulatory agents","literature review","pharmacological treatments"],"e_drugs":["remdesivir","tocilizumab","lopinavir-ritonavir drug combination","favipiravir"],"topics":["Treatment"],"weight":1,"_version_":1666138494591827971,"score":132.41489},{"pmid":32320825,"pmcid":"PMC7166307","title":"Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status.","text":["Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status.","Coronaviruses are a large group of viruses known to cause illnesses that vary between the common cold and more severe diseases to include severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). A novel coronavirus was identified in December 2019 in Wuhan city, Hubei province, China. This virus represents a new strain that has not been previously identified in humans. The virus is now known as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting disease is called coronavirus disease 2019 (COVID-19). The World Health Organization (WHO) declared the novel coronavirus outbreak a global pandemic in March 2020. Despite rigorous global containment and quarantine efforts, the incidence of COVID-19 continues to rise, with more than 1,948,617 laboratory-confirmed cases and over 121,846 deaths worldwide. Currently, no specific medication is recommended to treat COVID-19 patients. However, governments and pharmaceutical companies are struggling to quickly find an effective drug to defeat the coronavirus. In the current review, we summarize the existing state of knowledge about COVID-19, available medications, and treatment options. Favilavir is an antiviral drug that is approved in Japan for common influenza treatment and is now approved to treat symptoms of COVID-19 in China. Moreover, Chloroquine and hydroxychloroquine, drugs used to treat malaria and arthritis, respectively, were recommended by the National Health Commission of the People's Republic of China for treatment of COVID-19. Presently, chloroquine and hydroxychloroquine are under investigation by the US Food and Drug Administration (FDA) as a treatment for COVID-19. The first COVID-19 vaccine is not expected to be ready for clinical trials before the end of the year.","Infect Genet Evol","Abd El-Aziz, Tarek Mohamed","Stockand, James D","32320825"],"abstract":["Coronaviruses are a large group of viruses known to cause illnesses that vary between the common cold and more severe diseases to include severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). A novel coronavirus was identified in December 2019 in Wuhan city, Hubei province, China. This virus represents a new strain that has not been previously identified in humans. The virus is now known as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting disease is called coronavirus disease 2019 (COVID-19). The World Health Organization (WHO) declared the novel coronavirus outbreak a global pandemic in March 2020. Despite rigorous global containment and quarantine efforts, the incidence of COVID-19 continues to rise, with more than 1,948,617 laboratory-confirmed cases and over 121,846 deaths worldwide. Currently, no specific medication is recommended to treat COVID-19 patients. However, governments and pharmaceutical companies are struggling to quickly find an effective drug to defeat the coronavirus. In the current review, we summarize the existing state of knowledge about COVID-19, available medications, and treatment options. Favilavir is an antiviral drug that is approved in Japan for common influenza treatment and is now approved to treat symptoms of COVID-19 in China. Moreover, Chloroquine and hydroxychloroquine, drugs used to treat malaria and arthritis, respectively, were recommended by the National Health Commission of the People's Republic of China for treatment of COVID-19. Presently, chloroquine and hydroxychloroquine are under investigation by the US Food and Drug Administration (FDA) as a treatment for COVID-19. The first COVID-19 vaccine is not expected to be ready for clinical trials before the end of the year."],"journal":"Infect Genet Evol","authors":["Abd El-Aziz, Tarek Mohamed","Stockand, James D"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32320825","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.meegid.2020.104327","keywords":["covid-19","coronavirus","pathogenesis","sars-cov-2","severe acute respiratory syndrome","therapy","vaccines"],"locations":["Wuhan","Hubei","China","Japan","China"],"countries":["Japan","China"],"countries_codes":["JPN|Japan","CHN|China"],"e_drugs":["Hydroxychloroquine","Chloroquine"],"topics":["Treatment"],"weight":1,"_version_":1666138493599875072,"score":129.53297}]}